Make an Inquiry
Accelerating Polycythemia Vera Drug Development

Polycythemia vera presents significant therapeutic challenges due to its complex pathophysiology and the need for targeted, effective treatments. Protheragen is a specialized partner in preclinical drug development, dedicated to advancing novel therapeutics for Polycythemia vera. Leveraging extensive scientific expertise, Protheragen delivers comprehensive preclinical solutions encompassing target validation, lead optimization, pharmacology, and IND-enabling studies. Our advanced platforms integrate state-of-the-art molecular biology, in vitro and in vivo disease modeling, and robust bioanalytical capabilities to ensure data integrity and translational relevance. Protheragen’s commitment to regulatory compliance is reflected in rigorous study design and meticulous documentation, streamlining the pathway to clinical evaluation. By combining deep disease understanding with innovative technologies, Protheragen accelerates the development of high-potential candidates for Polycythemia vera. We are dedicated to enabling our partners to achieve therapeutic breakthroughs that address critical unmet patient needs.

What is Polycythemia VeraTargets for Polycythemia VeraDrug Discovery and Development ServicesWhy Choose Us

What is Polycythemia Vera

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by the clonal proliferation of erythroid, granulocytic, and megakaryocytic cells in the bone marrow, resulting in an absolute increase in red blood cell mass. The disease is most commonly caused by somatic mutations in the Janus kinase 2 (JAK2) gene—particularly the JAK2 V617F mutation—which leads to constitutive activation of the JAK-STAT signaling pathway. This aberrant signaling promotes uncontrolled hematopoietic cell growth and hypersensitivity to growth factors, manifesting as erythrocytosis, leukocytosis, and thrombocytosis. Over time, PV can progress to myelofibrosis or transform into acute myeloid leukemia. Clinically, PV presents with symptoms related to increased blood viscosity and abnormal platelet function, including headache, pruritus, splenomegaly, microvascular disturbances, and an elevated risk of arterial and venous thrombosis. Diagnosis is based on elevated hemoglobin or hematocrit levels, bone marrow biopsy revealing panmyelosis, and the presence of a JAK2 mutation, along with low serum erythropoietin. Treatment aims to reduce thrombotic risk and control blood counts, with first-line therapies including phlebotomy and cytoreductive agents such as hydroxyurea. For patients intolerant or resistant to hydroxyurea, ruxolitinib (a JAK1/2 inhibitor) and ropeginterferon alfa 2b are effective alternatives. Myelosuppressive agents like chlormethine hydrochloride may also be considered in select cases.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
ropeginterferon alfa 2b (Rec INN) 1335098-50-4
img-1092939-17-7941678-49-5-free-base-ruxolitinib-phosphate-prop-innm-usan ruxolitinib phosphate (Prop INNM; USAN) 1092939-17-7; 941678-49-5 (free base) C17 H18 N6 . H3 O4 P 404.36
img-127-07-1-hydroxyurea hydroxyurea 127-07-1 C H4 N2 O2 76.055
img-55-86-7-chlormethine-hydrochloride-rec-innmmechlorethamine chlormethine hydrochloride (Rec INNM); mechlorethamine hydrochloride (USAN); mustine hydrochoride (BANM); nitrogen Mustard 55-86-7 C5 H11 Cl2 N . Cl H 192.514

Learn More

Targets for Polycythemia Vera

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Janus kinase 1 JAK1
Janus kinase 2 JAK2
interferon alpha and beta receptor subunit 2 IFNAR2
Ribonucleoside-diphosphate reductase
tyrosine kinase 2 TYK2
Histone deacetylase (nonspecified subtype)
interleukin 1 beta IL1B
hepcidin antimicrobial peptide HAMP
solute carrier family 40 member 1 SLC40A1
tumor necrosis factor TNF

Polycythemia vera (PV) is primarily driven by dysregulation of the JAK-STAT signaling pathway, with the JAK2 V617F mutation acting as the central molecular driver. This mutation leads to constitutive activation of JAK2, promoting uncontrolled erythroid cell proliferation independent of normal cytokine regulation. JAK1 and TYK2, closely related kinases, further modulate cytokine signaling and inflammatory responses in PV, while the KIT receptor tyrosine kinase supports hematopoietic stem cell survival and can cooperate with JAK2 in disease progression. Additionally, iron homeostasis is significantly altered in PV; hepcidin (HAMP) and ferroportin (SLC40A1) regulate systemic iron availability, which is suppressed to meet the increased demands of excessive erythropoiesis, further fueling the disease process. Therapeutically, targeting these pathways has yielded significant clinical advances. JAK2 inhibitors, such as ruxolitinib, are approved for PV and effectively reduce hematocrit, symptom burden, and splenomegaly. Pan-JAK inhibitors that also target JAK1 and TYK2 are under investigation to modulate both proliferative and inflammatory aspects of PV. While KIT inhibitors have limited efficacy in PV, they may hold promise in specific disease contexts. Modulation of iron metabolism, through agents that mimic or enhance hepcidin activity or directly target ferroportin, represents a novel therapeutic avenue currently in preclinical and early clinical development, aiming to restrict iron availability and control erythrocytosis. These targeted approaches are shaping a precision medicine framework for PV management.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Polycythemia Vera drug discovery by providing robust, sensitive platforms for compound screening and mechanistic studies. We offer high-throughput biochemical and cell-based assays targeting JAK2/STAT, erythropoietin receptor, and key hematopoietic regulators. Methods include ATP, chemiluminescent, ELISA, fluorescent, luciferase, and binding assays, enabling comprehensive evaluation of cell viability, target engagement, and biomarker modulation. Quantitative parameters such as IC-50, EC-50, Ki, Kd, and MEC guide lead optimization. Our validated models and rigorous analytics deliver actionable data, supporting informed decisions and efficient development of targeted therapies for Polycythemia Vera.

Hepcidin Antimicrobial Peptide Janus Kinase 1
Janus Kinase 2 Tumor Necrosis Factor
Tyrosine Kinase 2

Learn More

Why Choose Us

Choosing Protheragen for your Polycythemia vera drug development needs means partnering with a team that is deeply specialized in this complex field. At Protheragen, we bring together leading scientific experts and cutting-edge technology platforms to address the unique challenges of Polycythemia vera research and therapeutic development. Our professional teams are dedicated to delivering innovative solutions, leveraging years of experience and a proven track record in preclinical drug development services. We pride ourselves on our unwavering commitment to quality, adhering to the highest industry standards and maintaining strict regulatory compliance throughout every stage of the development process. Protheragen’s reliability is demonstrated through our successful collaborations and the trust we have built with our partners worldwide. Above all, we are passionate about advancing therapeutics for Polycythemia vera, striving to make a meaningful difference in the lives of patients by bringing safe and effective treatments closer to reality. When you choose Protheragen, you are choosing a partner devoted to excellence, integrity, and progress in the fight against Polycythemia vera.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Polycythemia vera?

A: Polycythemia vera (PV) presents unique preclinical research challenges, including the development of reliable in vitro and in vivo models that accurately mimic the human disease. The heterogeneity of PV, especially in terms of JAK2 mutation status and disease progression, complicates model selection and data interpretation. Additionally, evaluating drug efficacy and safety requires robust biomarkers and endpoints that are predictive of clinical outcomes. Our company addresses these challenges by employing advanced genetic models, utilizing patient-derived cells, and integrating multi-omics approaches to ensure translational relevance.

Q: What are the key regulatory considerations for preclinical drug development targeting Polycythemia vera?

A: Regulatory agencies such as the FDA and EMA require comprehensive preclinical data to support Investigational New Drug (IND) applications for PV therapies. This includes pharmacology, toxicology, pharmacokinetics, and proof-of-concept efficacy studies. Special attention must be paid to demonstrating selectivity for disease targets (e.g., JAK2 V617F), minimizing off-target effects, and providing a strong scientific rationale for the proposed indication. Our team has extensive experience designing regulatory-compliant preclinical programs, preparing IND-enabling study packages, and facilitating communication with regulatory authorities.

Q: What are the main technical aspects to consider when conducting preclinical research for Polycythemia vera?

A: Technical considerations in PV research include selecting appropriate cell lines and animal models, optimizing dosing regimens, and developing sensitive assays for hematological endpoints. For PV, it is crucial to assess drug effects on erythropoiesis, thrombopoiesis, and myeloproliferation, as well as potential impacts on splenomegaly and thrombotic risk. Our company leverages state-of-the-art technologies such as flow cytometry, next-generation sequencing, and digital pathology to generate high-quality, reproducible data.

Q: What are the typical timeline and cost considerations for preclinical drug development in Polycythemia vera?

A: Preclinical development for PV drug candidates generally spans 12–24 months, depending on the complexity of the program and regulatory requirements. Costs can vary widely, typically ranging from $2 million to $5 million for a full IND-enabling package, including efficacy, safety pharmacology, toxicology, and CMC (Chemistry, Manufacturing, and Controls) studies. Our company offers tailored project management and budgeting solutions to streamline timelines and control costs while ensuring regulatory compliance and scientific rigor.

Q: What are the most important success factors in preclinical drug development for Polycythemia vera?

A: Key success factors include the selection of validated disease models, clear definition of translational biomarkers, early identification of safety liabilities, and a strong scientific rationale for target selection. Collaboration between multidisciplinary teams—spanning molecular biology, pharmacology, toxicology, and regulatory affairs—is essential. Our expertise in integrated preclinical services, combined with our focus on innovation and quality, enables our clients to advance their PV drug candidates efficiently and with a high probability of success.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.